GI Oncology
Bemarituzumab is a humanized monoclonal antibody that is selective for FGFR2b.
Rectal gastrointestinal stromal tumors are rare, making up only 0.1% of all rectal neoplasms and about 5.0% of all GISTs.
Researchers can quantify absorbed doses through serial postinfusion scintigraphy measurements of the γ-emissions.
Dr. Yarchoan details neoantigen-specific T cell responses assessed in the study.
Determining which patients can benefit the most from immunotherapy remains elusive.
Researchers used descriptive statistics to analyze first-line treatment patterns.
Dr. Sethi continues his comments on NER deficiency in gastric cancer cell lines in response to cisplatin treatment.
Dr. Sethi discusses homologous recombination and nucleotide excision repair pathways in DNA repair for cancers.
Researchers noted that neoadjuvant anti–PD-1 treatment may serve as a curative-intent therapy.
Matthew Strickland, MD, discusses the current management of defective mismatch repair in gastroesophageal adenocarcinoma.
Researchers conducted a comprehensive analysis to determine the association between HCC disease stage and prognosis.
RNA biomarkers are not reliant on age-related methylation patterns that may result in test performance variability.
The effects of primary tumor and LN volume on clinical outcomes in ESCC following neoadjuvant CCRT and surgery are unknown.
PRECEDE offers testing for individuals at high risk of pancreatic cancer, with multiple testing sites located globally.
Dr. Rodón Ahnert compares the differences of sacituzumab tirumotecan use in the second- vs third-line setting for patients.
Dr. Goel discusses how his team's liquid biopsy can be used with CA19-9 to boost the accuracy of detecting pancreatic cancer.
Colorectal cancer screening intervals can potentially be extended to 15 years to avoid unnecessary invasive examinations.
Lenvatinib is a common treatment for patients with uHCC, and has been used with pembrolizumab for other diseases.
Pembrolizumab Shows Promise as a First-line Treatment for Advanced Gastric, Gastroesophageal Cancers
The final results from the KEYNOTE-811 trial will determine if Keytruda will receive continued approval from the FDA.
Researchers analyzed the utilization and outcomes of multigene panel GT in patients with PDAC.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.